Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

microbiome SER-155

An orally bioavailable, cultivated microbiome therapeutic composed of a consortium of fermented bacterial species that were specifically selected to decrease infection and translocation of antibiotic-resistant bacteria in the gastrointestinal (GI) tract, with potential immunomodulating activity. Upon oral administration, microbiome SER-155 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the GI tact and may re-establish a healthy microbiome in the GI tract. This may enhance the patients' immunological activity and lower the risk of GI antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease (GvHD) in patients undergoing solid organ and allogeneic stem cell transplantation.
Synonym:microbiome-based therapeutic SER-155
Code name:SER 155
SER-155
SER155
Search NCI's Drug Dictionary